

Wyost® (denosumab-bbdz) - First-time interchangeable biosimilar launch

 On June 2, 2025, Sandoz launched <u>Wyost (denosumab-bbdz)</u>, biosimilar and *interchangeable* to Amgen's Xgeva[®] (denosumab).

Wyost is available at a list price (Wholesale Acquisition Cost [WAC]) 7% below the current Xgeva list price (\$3208.26 per package).

- Wyost was FDA-approved in March 2024.
- Additional biosimilars to Xgeva have been approved with pending launch dates:
 - Samsung Bioepis' Xbryk™ (denosumab-dssb)
 - Celltrion's Osenvelt® (denosumab-bmwo)
 - Fresenius Kabi's Bomyntra® (denosumab-bnht).
- Wyost and Xgeva share the following indications:
 - Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
 - Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
 - Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.